Allergic
bronchopulmonary aspergillosis (ABPA) is type I and II hypersensitivity
reaction to aspergillus fumigates (a species of fungus which is found in
household dust, soil and plants) following colonization in patients’ airway
with background of asthma or cystic fibrosis [1-4]. This disease also affects
patients with chronic granulomatous disease, bronchiectasis, lung transplant
recipient and hyper immunoglobulinemia IgE. The main symptoms including
exacerbation of asthma and productive cough usually respond well to
prednisolone and this is necessary to consider early diagnosis of ABPA in any
patient with bronchial asthma at early stages to prevent bronchiectasis
development and permanent damage. Following CD (4) +Th2 cells activation in
response to antigens of Aspergillus fumigatus, immunoglobulins are produced
(IgE, IgG and IgA). Diagnosis of ABPA is considered based on clinical findings,
radiological abnormalities and biological criteria [3]. The mainstay of
treatment is corticosteroids which is considered for flare up of disease or
acute phase and to be continued for 6-8 weeks. In addition, antifungal
medication, itraconazole, is recommended nowadays with daily dose of 200 mg,
for period of 16 weeks [4].